Results 191 to 200 of about 537,284 (311)

In Silico Studies of Potent Tyrosine Kinase Inhibitors: Molecular Docking and Pharmacophore Modeling Approaches. [PDF]

Molecules
Mavridis E, Pontiki E, Hadjipavlou-Litina D.   +2 more
europepmc   +1 more source

Macrophage‐to‐Myofibroblast Transdifferentiation Contributes to Pulmonary Fibrosis via the MERTK‐SPP1‐SRC‐TKS5 Signaling Axis

Advanced Science, EarlyView.
MERTK is upregulated in fibrotic macrophages and regulates the expression and activity of SRC and TKS5 through SPP1, mediating transdifferentiation of macrophages‐to‐myofibroblasts (MMT) and promoting pulmonary fibrosis. The figure was created with BioRender.com.
Yungeng Wei, Hua Guo, Xiangsheng Yang, Xiao Xiao Tang   +3 more
wiley   +1 more source

Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). [PDF]

Virus Res
Tjärnhage E, Våtsveen TK, Raki M, Nemazee D, Farhan H, Munthe L, Grodeland G.   +6 more
europepmc   +1 more source

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

Retraction: Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease. [PDF]

Clin Sci (Lond)
Zhuang S, Liu F, Wang L, Qi H, Wang J, Wang Y, Jiang W, Xu L, Liu N.   +8 more
europepmc   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Advanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao   +7 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease. [PDF]

Molecules
Ye Q, Ma S.
europepmc   +1 more source

Lactoferrin Deficiency During Lactation Causes Adult Obesity‐Related Metabolic Disease Through Persistent Adipose Dysfunction Driven by Impaired Adipocyte Development

Advanced Science, EarlyView.
Lactational lactoferrin deficiency exerts lasting effects on epididymal adipose tissue development from lactation into adulthood: it impairs adipocyte hyperplasia and induces pathological hypertrophy, resulting in lower body weight yet exacerbated metabolic dysfunction under a high‐fat diet in adulthood.
Qin An, Yunxia Zou, Wenli Wang, Zhimei Cheng, Zhuoxing Zhang, Ruwei Liu, Xiong Wang, Kunlun Huang, Fangrong Ding, Yunping Dai, Qingyong Meng, Yali Zhang   +11 more
wiley   +1 more source

A Novel Tyrosine Kinase Axis in Innate Immune Signaling. [PDF]

Viruses
Das S, Sengupta P, Veleeparambil M, Chattopadhyay S.   +3 more
europepmc   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

Advanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia, Hui You, Ke Zhang, Hui Jiang, Hongping Liu, Lianghua Liu, Aijie Zhang, You Zhou   +7 more
wiley   +1 more source